中川 俊作

Last Update: 2019/06/03 14:52:22

Print

Name(Kanji/Kana/Abecedarium Latinum)
中川 俊作/ナカガワ シュンサク/Nakagawa, Syunsaku
Primary Affiliation(Org1/Job title)
Kyoto University Hospital/Assistant Professor
Affiliated programs (koza)
Org1 Job title
Graduate Schools Pharmaceutical Sciences Assistant Professor
Academic Degree
Field(Japanese) Field(English) University(Japanese) University(English) Method
修士(薬学) 京都大学
博士(薬学) 京都大学
researchmap URL
https://researchmap.jp/7000009902
Research Topics
(Japanese)
薬物の副作用発現に関わるメカニズム解明と、予測法・治療法の開発
Fields of research (key words)
Key words(Japanese) Key words(English)
医療薬剤学
毒性学
薬理学
腎臓学
Published Papers
Author Author(Japanese) Author(English) Title Title(Japanese) Title(English) Bibliography Bibliography(Japanese) Bibliography(English) Publication date Refereed paper Language Publishing type Disclose
Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Wakatsuki S, Araki T, Kaneko S, Nakagawa T, Matsubara K Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Wakatsuki S, Araki T, Kaneko S, Nakagawa T, Matsubara K Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T, Yonezawa A, Omura T, Nakagawa S, Wakatsuki S, Araki T, Kaneko S, Nakagawa T, Matsubara K Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Scientific reports, 7, 1, 5947 Scientific reports, 7, 1, 5947 Scientific reports, 7, 1, 5947 2017/07 Refereed Disclose to all
Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S, Yonezawa A, Matsubara K, Muto M Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S, Yonezawa A, Matsubara K, Muto M Nishikawa Y, Funakoshi T, Horimatsu T, Miyamoto S, Matsubara T, Yanagita M, Nakagawa S, Yonezawa A, Matsubara K, Muto M Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer chemotherapy and pharmacology, 79, 3, 629-633 Cancer chemotherapy and pharmacology, 79, 3, 629-633 Cancer chemotherapy and pharmacology, 79, 3, 629-633 2017/03 Refereed Disclose to all
Hirakawa H, Nakashima C, Nakamura T, Masuda M, Funakoshi T, Nakagawa S, Horimatsu T, Matsubara K, Muto M, Kimura S, Sueoka-Aragane N Hirakawa H, Nakashima C, Nakamura T, Masuda M, Funakoshi T, Nakagawa S, Horimatsu T, Matsubara K, Muto M, Kimura S, Sueoka-Aragane N Hirakawa H, Nakashima C, Nakamura T, Masuda M, Funakoshi T, Nakagawa S, Horimatsu T, Matsubara K, Muto M, Kimura S, Sueoka-Aragane N Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. Chemotherapy for primary mediastinal yolk sac tumor in a patient undergoing chronic hemodialysis: a case report. Journal of medical case reports, 11, 1, 43 Journal of medical case reports, 11, 1, 43 Journal of medical case reports, 11, 1, 43 2017/02 Refereed Disclose to all
Leaf IA, Nakagawa S, Johnson BG, Cha JJ, Mittelsteadt K, Guckian KM, Gomez IG, Altemeier WA, Duffield JS Leaf IA, Nakagawa S, Johnson BG, Cha JJ, Mittelsteadt K, Guckian KM, Gomez IG, Altemeier WA, Duffield JS Leaf IA, Nakagawa S, Johnson BG, Cha JJ, Mittelsteadt K, Guckian KM, Gomez IG, Altemeier WA, Duffield JS Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury. The Journal of clinical investigation, 127, 1, 321-334 The Journal of clinical investigation, 127, 1, 321-334 The Journal of clinical investigation, 127, 1, 321-334 2017/01 Refereed Disclose to all
Nakagawa S Nakagawa S Nakagawa S [Identification of Biomarkers for Tubular Injury and Interstitial Fibrosis in Chronic Kidney Disease]. [Identification of Biomarkers for Tubular Injury and Interstitial Fibrosis in Chronic Kidney Disease]. [Identification of Biomarkers for Tubular Injury and Interstitial Fibrosis in Chronic Kidney Disease]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 137, 11, 1355-1360 Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 137, 11, 1355-1360 Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 137, 11, 1355-1360 2017 Refereed Disclose to all
Jin C, Yao Y, Yonezawa A, Imai S, Yoshimatsu H, Otani Y, Omura T, Nakagawa S, Nakagawa T, Matsubara K Jin C, Yao Y, Yonezawa A, Imai S, Yoshimatsu H, Otani Y, Omura T, Nakagawa S, Nakagawa T, Matsubara K Jin C, Yao Y, Yonezawa A, Imai S, Yoshimatsu H, Otani Y, Omura T, Nakagawa S, Nakagawa T, Matsubara K Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane. Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane. Riboflavin Transporters RFVT/SLC52A Mediate Translocation of Riboflavin, Rather than FMN or FAD, across Plasma Membrane. Biological & pharmaceutical bulletin, 40, 11, 1990-1995 Biological & pharmaceutical bulletin, 40, 11, 1990-1995 Biological & pharmaceutical bulletin, 40, 11, 1990-1995 2017 Refereed Disclose to all
Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K Otani Y, Yonezawa A, Tsuda M, Imai S, Ikemi Y, Nakagawa S, Omura T, Nakagawa T, Yano I, Matsubara K Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats. PloS one, 12, 1, e0169588 PloS one, 12, 1, e0169588 PloS one, 12, 1, e0169588 2017 Refereed Disclose to all
Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K Yoshimatsu H, Yonezawa A, Yamanishi K, Yao Y, Sugano K, Nakagawa S, Imai S, Omura T, Nakagawa T, Yano I, Masuda S, Inui K, Matsubara K Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Scientific reports, 6, 27557 Scientific reports, 6, 27557 Scientific reports, 6, 27557 2016/06 Refereed Disclose to all
Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. Drug metabolism and pharmacokinetics, 30, 6, 441-448 Drug metabolism and pharmacokinetics, 30, 6, 441-448 Drug metabolism and pharmacokinetics, 30, 6, 441-448 2015/12 Refereed Disclose to all
Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, Yamamoto Y, Okuno Y, Miyamoto S, Nakagawa H, Matsubara K, Chiba T, Muto M Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, Yamamoto Y, Okuno Y, Miyamoto S, Nakagawa H, Matsubara K, Chiba T, Muto M Kikuchi O, Ohashi S, Nakai Y, Nakagawa S, Matsuoka K, Kobunai T, Takechi T, Amanuma Y, Yoshioka M, Ida T, Yamamoto Y, Okuno Y, Miyamoto S, Nakagawa H, Matsubara K, Chiba T, Muto M Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression. American journal of cancer research, 5, 8, 2431-2440 American journal of cancer research, 5, 8, 2431-2440 American journal of cancer research, 5, 8, 2431-2440 2015 Refereed Disclose to all
Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, Matsubara T, Iehara N, Igarashi Y, Yamada H, Fukatsu A, Yanagita M, Matsubara K, Masuda S Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, Matsubara T, Iehara N, Igarashi Y, Yamada H, Fukatsu A, Yanagita M, Matsubara K, Masuda S Nakagawa S, Nishihara K, Miyata H, Shinke H, Tomita E, Kajiwara M, Matsubara T, Iehara N, Igarashi Y, Yamada H, Fukatsu A, Yanagita M, Matsubara K, Masuda S Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. Molecular Markers of Tubulointerstitial Fibrosis and Tubular Cell Damage in Patients with Chronic Kidney Disease. PloS one, 10, 8, e0136994 PloS one, 10, 8, e0136994 PloS one, 10, 8, e0136994 2015 Refereed Disclose to all
Koyama S, Omura T, Yonezawa A, Imai S, Nakagawa S, Nakagawa T, Yano I, Matsubara K Koyama S, Omura T, Yonezawa A, Imai S, Nakagawa S, Nakagawa T, Yano I, Matsubara K Koyama S, Omura T, Yonezawa A, Imai S, Nakagawa S, Nakagawa T, Yano I, Matsubara K Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. PloS one, 10, 8, e0136176 PloS one, 10, 8, e0136176 PloS one, 10, 8, e0136176 2015 Refereed Disclose to all
Yonezawa A, Kajiwara M, Minami I, Omura T, Nakagawa S, Matsubara K Yonezawa A, Kajiwara M, Minami I, Omura T, Nakagawa S, Matsubara K Yonezawa A, Kajiwara M, Minami I, Omura T, Nakagawa S, Matsubara K [The Contribution of GMP-grade Hospital Preparation to Translational Research]. [The Contribution of GMP-grade Hospital Preparation to Translational Research]. [The Contribution of GMP-grade Hospital Preparation to Translational Research]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 135, 8, 943-947 Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 135, 8, 943-947 Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 135, 8, 943-947 2015 Refereed Disclose to all
Nakagawa S, Omura T, Yonezawa A, Yano I, Nakagawa T, Matsubara K. Nakagawa S, Omura T, Yonezawa A, Yano I, Nakagawa T, Matsubara K. Nakagawa S, Omura T, Yonezawa A, Yano I, Nakagawa T, Matsubara K. Extracellular nucleotides from dying cells act as molecular signals to promote wound repair in renal tubular injury Extracellular nucleotides from dying cells act as molecular signals to promote wound repair in renal tubular injury Extracellular nucleotides from dying cells act as molecular signals to promote wound repair in renal tubular injury Am J Physiol Renal Physiol, 307, 12, 1404-1411 Am J Physiol Renal Physiol, 307, 12, 1404-1411 Am J Physiol Renal Physiol, 307, 12, 1404-1411 2014/12 Refereed English Research paper(scientific journal) Disclose to all
H. Yoshimatsu; A. Yonezawa; Y. Yao; K. Sugano; S. Nakagawa; T. Omura; K. Matsubara H. Yoshimatsu; A. Yonezawa; Y. Yao; K. Sugano; S. Nakagawa; T. Omura; K. Matsubara H. Yoshimatsu; A. Yonezawa; Y. Yao; K. Sugano; S. Nakagawa; T. Omura; K. Matsubara Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption Functional involvement of RFVT3/SLC52A3 in intestinal riboflavin absorption American Journal of Physiology - Gastrointestinal and Liver Physiology, 306, 2, G102-G110 American Journal of Physiology - Gastrointestinal and Liver Physiology, 306, 2, G102-G110 American Journal of Physiology - Gastrointestinal and Liver Physiology, 306, 2, G102-G110 2014 Refereed English Disclose to all
Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, Heinecke JW, Hamerman JA, Altemeier WA, Duffield JS. Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, Heinecke JW, Hamerman JA, Altemeier WA, Duffield JS. Campanholle G, Mittelsteadt K, Nakagawa S, Kobayashi A, Lin SL, Gharib SA, Heinecke JW, Hamerman JA, Altemeier WA, Duffield JS. TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury. TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury. TLR-2/TLR-4 TREM-1 signaling pathway is dispensable in inflammatory myeloid cells during sterile kidney injury. PLoS One, 8, 7, e68640 PLoS One, 8, 7, e68640 PLoS One, 8, 7, e68640 2013/06 Refereed English Research paper(scientific journal) Disclose to all
K. Nishihara; S. Masuda; H. Shinke; A. Ozawa; T. Ichimura; A. Yonezawa; S. Nakagawa; K.-I. Inui; J.V. Bonventre; K. Matsubara K. Nishihara; S. Masuda; H. Shinke; A. Ozawa; T. Ichimura; A. Yonezawa; S. Nakagawa; K.-I. Inui; J.V. Bonventre; K. Matsubara K. Nishihara; S. Masuda; H. Shinke; A. Ozawa; T. Ichimura; A. Yonezawa; S. Nakagawa; K.-I. Inui; J.V. Bonventre; K. Matsubara Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity Biochemical Pharmacology, 85, 4, 570-582 Biochemical Pharmacology, 85, 4, 570-582 Biochemical Pharmacology, 85, 4, 570-582 2013/02/15 Refereed English Disclose to all
S. Nakagawa; K. Nishihara; K.-I. Inui; S. Masuda S. Nakagawa; K. Nishihara; K.-I. Inui; S. Masuda S. Nakagawa; K. Nishihara; K.-I. Inui; S. Masuda Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury European Journal of Pharmacology, 696, 1-3, 143-154 European Journal of Pharmacology, 696, 1-3, 143-154 European Journal of Pharmacology, 696, 1-3, 143-154 2012/12/05 Refereed English Disclose to all
K. Nishihara; S. Masuda; S. Nakagawa; A. Yonezawa; T. Ichimura; J.V. Bonventre; K.-I. Inui K. Nishihara; S. Masuda; S. Nakagawa; A. Yonezawa; T. Ichimura; J.V. Bonventre; K.-I. Inui K. Nishihara; S. Masuda; S. Nakagawa; A. Yonezawa; T. Ichimura; J.V. Bonventre; K.-I. Inui Impact of cyclin B2 and cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats Impact of cyclin B2 and cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats Impact of cyclin B2 and cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats American Journal of Physiology - Renal Physiology, 298, 4, F923-F934 American Journal of Physiology - Renal Physiology, 298, 4, F923-F934 American Journal of Physiology - Renal Physiology, 298, 4, F923-F934 2010/04 Refereed English Disclose to all
S. Nakagawa; S. Masuda; K. Nishihara; K.-i. Inui S. Nakagawa; S. Masuda; K. Nishihara; K.-i. Inui S. Nakagawa; S. Masuda; K. Nishihara; K.-i. Inui mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats Biochemical Pharmacology, 79, 1, 67-76 Biochemical Pharmacology, 79, 1, 67-76 Biochemical Pharmacology, 79, 1, 67-76 2010/01/01 Refereed English Disclose to all

  • <<
  • >>
Title language:
External funds: competitive funds and Grants-in-Aid for Scientific Research (Kakenhi)
Type Position Title(Japanese) Title(English) Period
若手研究(B) Representative 薬剤性腎障害の重篤化阻止に向けた腎臓内在性炎症抑制システムの役割解明 2014/04/01-2016/03/31
若手研究(B) Representative 薬物による尿細管間質性腎炎の発症機序解明 2016/04/01-2018/03/31
基盤研究(C) Representative 薬物誘発性腎線維化に対する治療法の探索 2018/04/01-2021/03/31
基盤研究(C) Representative 薬物誘発性腎線維化に対する治療法の探索 (平成30年度分) 2018/04/01-2019/03/31
Teaching subject(s)
Name(Japanese) Name(English) Term Department Period
薬剤・薬理学概論 Clinical Pharmacy and Pharmacology 前期後半 医学部(人間健康科学科) 2015/04-2016/03
基盤医療薬剤学実習 Laboratory Practice in Basic Clinical Pharmacy 通年不定 薬学研究科 2016/04-2017/03
基盤医療薬剤学実験 Research in Basic Clinical Pharmacy 通年不定 薬学研究科 2016/04-2017/03
基盤医療薬剤学演習 Seminar in Basic Clinical Pharmacy 通年不定 薬学研究科 2016/04-2017/03
臨床薬学実習Ⅱ Laboratory Practice in Clinical Pharmacy II 通年不定 薬学研究科 2016/04-2017/03
臨床薬学実習Ⅰ Laboratory Practice in Clinical Pharmacy I 通年不定 薬学研究科 2016/04-2017/03
臨床薬学演習Ⅲ Seminar for Clinical Pharmacy III 通年不定 薬学研究科 2016/04-2017/03
臨床薬学演習Ⅱ Seminar for Clinical Pharmacy II 通年不定 薬学研究科 2016/04-2017/03
臨床薬学演習Ⅰ Seminar for Clinical Pharmacy I 通年不定 薬学研究科 2016/04-2017/03
薬剤・薬理学概論 Clinical Pharmacy and Pharmacology 前期後半 医学部(人間健康科学科) 2016/04-2017/03
薬学研究実験Ⅲ Research in Pharmaceutical Sciences III 通年不定 薬学研究科 2016/04-2017/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 通年不定 薬学研究科 2016/04-2017/03
薬学研究実験Ⅰ Research in Pharmaceutical Sciences I 通年不定 薬学研究科 2016/04-2017/03
基盤医療薬剤学実習 Laboratory Practice in Basic Clinical Pharmacy 通年不定 薬学研究科 2017/04-2018/03
基盤医療薬剤学実験 Research in Basic Clinical Pharmacy 通年不定 薬学研究科 2017/04-2018/03
基盤医療薬剤学演習 Seminar in Basic Clinical Pharmacy 通年不定 薬学研究科 2017/04-2018/03
臨床薬学実習Ⅱ Laboratory Practice in Clinical Pharmacy II 通年不定 薬学研究科 2017/04-2018/03
臨床薬学実習Ⅰ Laboratory Practice in Clinical Pharmacy I 通年不定 薬学研究科 2017/04-2018/03
臨床薬学演習Ⅲ Seminar for Clinical Pharmacy III 通年不定 薬学研究科 2017/04-2018/03
臨床薬学演習Ⅱ Seminar for Clinical Pharmacy II 通年不定 薬学研究科 2017/04-2018/03
臨床薬学演習Ⅰ Seminar for Clinical Pharmacy I 通年不定 薬学研究科 2017/04-2018/03
薬剤・薬理学概論 Clinical Pharmacy and Pharmacology 前期後半 医学部(人間健康科学科) 2017/04-2018/03
薬学研究実験Ⅲ Research in Pharmaceutical Sciences III 通年不定 薬学研究科 2017/04-2018/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 通年不定 薬学研究科 2017/04-2018/03
薬学研究実験Ⅰ Research in Pharmaceutical Sciences I 通年不定 薬学研究科 2017/04-2018/03
基盤医療薬剤学実習 Laboratory Practice in Basic Clinical Pharmacy 通年不定 薬学研究科 2018/04-2019/03
基盤医療薬剤学実験 Research in Basic Clinical Pharmacy 通年不定 薬学研究科 2018/04-2019/03
基盤医療薬剤学演習 Seminar in Basic Clinical Pharmacy 通年不定 薬学研究科 2018/04-2019/03
臨床薬学実習Ⅱ Laboratory Practice in Clinical Pharmacy II 通年不定 薬学研究科 2018/04-2019/03
臨床薬学実習Ⅰ Laboratory Practice in Clinical Pharmacy I 通年不定 薬学研究科 2018/04-2019/03
臨床薬学演習Ⅲ Seminar for Clinical Pharmacy III 通年不定 薬学研究科 2018/04-2019/03
臨床薬学演習Ⅱ Seminar for Clinical Pharmacy II 通年不定 薬学研究科 2018/04-2019/03
臨床薬学演習Ⅰ Seminar for Clinical Pharmacy I 通年不定 薬学研究科 2018/04-2019/03
薬剤・薬理学概論 Clinical Pharmacy and Pharmacology 前期後半 医学部(人間健康科学科) 2018/04-2019/03
薬学研究実験Ⅲ Research in Pharmaceutical Sciences III 通年不定 薬学研究科 2018/04-2019/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 後期前期 薬学研究科 2018/04-2019/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 通年不定 薬学研究科 2018/04-2019/03
薬学研究実験Ⅰ Research in Pharmaceutical Sciences I 後期前期 薬学研究科 2018/04-2019/03
薬学研究実験Ⅰ Research in Pharmaceutical Sciences I 通年不定 薬学研究科 2018/04-2019/03
基盤医療薬剤学実習 Laboratory Practice in Basic Clinical Pharmacy 通年不定 薬学研究科 2019/04-2020/03
基盤医療薬剤学実験 Research in Basic Clinical Pharmacy 通年不定 薬学研究科 2019/04-2020/03
基盤医療薬剤学演習 Seminar in Basic Clinical Pharmacy 通年不定 薬学研究科 2019/04-2020/03
病院薬学特論 Advanced Hospital Pharmacy 後期不定 薬学研究科 2019/04-2020/03
臨床薬学実習Ⅱ Laboratory Practice in Clinical Pharmacy II 通年不定 薬学研究科 2019/04-2020/03
臨床薬学実習Ⅰ Laboratory Practice in Clinical Pharmacy I 通年不定 薬学研究科 2019/04-2020/03
臨床薬学演習Ⅲ Seminar for Clinical Pharmacy III 通年不定 薬学研究科 2019/04-2020/03
臨床薬学演習Ⅱ Seminar for Clinical Pharmacy II 通年不定 薬学研究科 2019/04-2020/03
臨床薬学演習Ⅰ Seminar for Clinical Pharmacy I 通年不定 薬学研究科 2019/04-2020/03
薬剤・薬理学概論 Clinical Pharmacy and Pharmacology 前期後半 医学部(人間健康科学科) 2019/04-2020/03
薬学研究実験Ⅲ Research in Pharmaceutical Sciences III 後期不定 薬学研究科 2019/04-2020/03
薬学研究実験Ⅲ Research in Pharmaceutical Sciences III 通年不定 薬学研究科 2019/04-2020/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 前期不定 薬学研究科 2019/04-2020/03
薬学研究実験Ⅱ Research in Pharmaceutical Sciences II 通年不定 薬学研究科 2019/04-2020/03
薬学研究実験Ⅰ Research in Pharmaceutical Sciences I 通年不定 薬学研究科 2019/04-2020/03

  • <<
  • >>
Experience of living abroad
Organization Department Research theme Country Period
University of Washington Division of Nephrology Molecular mechanisms of sterile inflammation in kidney アメリカ合衆国 2012/09/01-2013/08/31